A Nomogram Based on Apelin-12 for the Prediction of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention among Patients with ST-Segment Elevation Myocardial Infarction

<div>Kaplan-Meier survival curves of the evaluation and validation cohorts categorized into low- and high-risk groups. A significant association between the risk score and MACEs was observed in the evaluation cohort (a) and confirmed in the validation cohort (b). Survival curves between the higher apelin-12 group (&gt;0.76 ng/mL) and lower apelin-12 group (≤0.76 ng/mL) in the evaluation cohort (c) and the validation cohort (d).</div>

Cardiovascular Therapeutics

fig4

Figure 4

Figure 4: A Nomogram Based on Apelin-12 for the Prediction of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention among Patients with ST-Segment Elevation Myocardial Infarction 

Figure 4 | A Nomogram Based on Apelin-12 for the Prediction of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention among Patients with ST-Segment Elevation Myocardial Infarction 